A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy
We provide a comprehensive review of current approved systemic treatment strategies for advanced hepatocellular carcinoma (HCC), starting with the phase III clinical trial of sorafenib which was the first to definitively show a survival benefit. After this trial, there was an initial period of littl...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/9/2506 |
| _version_ | 1797602901275705344 |
|---|---|
| author | Alexander Lazzaro Kevan L. Hartshorn |
| author_facet | Alexander Lazzaro Kevan L. Hartshorn |
| author_sort | Alexander Lazzaro |
| collection | DOAJ |
| description | We provide a comprehensive review of current approved systemic treatment strategies for advanced hepatocellular carcinoma (HCC), starting with the phase III clinical trial of sorafenib which was the first to definitively show a survival benefit. After this trial, there was an initial period of little progress. However, in recent years, an explosion of new agents and combinations of agents has resulted in a markedly improved outlook for patients. We then provide the authors’ current approach to therapy, i.e., “How We Treat HCC”. Promising future directions and important gaps in therapy that persist are finally reviewed. HCC is a highly prevalent cancer worldwide and the incidence is growing due not only to alcoholism, hepatitis B and C, but also to steatohepatitis. HCC, like renal cell carcinoma and melanoma, is a cancer largely resistant to chemotherapy but the advent of anti-angiogenic, targeted and immune therapies have improved survival for all of these cancers. We hope this review will heighten interest in the field of HCC therapies, provide a clear outline of the current data and strategy for treatment, and sensitize readers to new developments that are likely to emerge in the near future. |
| first_indexed | 2024-03-11T04:22:06Z |
| format | Article |
| id | doaj.art-3fddeef6544e4ac18a4a477ebb57a1b6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T04:22:06Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-3fddeef6544e4ac18a4a477ebb57a1b62023-11-17T22:40:40ZengMDPI AGCancers2072-66942023-04-01159250610.3390/cancers15092506A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic TherapyAlexander Lazzaro0Kevan L. Hartshorn1Department of Medicine, Boston Medical Center, Boston, MA 02118, USASection of Hematology Oncology, Boston University Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston, MA 02118, USAWe provide a comprehensive review of current approved systemic treatment strategies for advanced hepatocellular carcinoma (HCC), starting with the phase III clinical trial of sorafenib which was the first to definitively show a survival benefit. After this trial, there was an initial period of little progress. However, in recent years, an explosion of new agents and combinations of agents has resulted in a markedly improved outlook for patients. We then provide the authors’ current approach to therapy, i.e., “How We Treat HCC”. Promising future directions and important gaps in therapy that persist are finally reviewed. HCC is a highly prevalent cancer worldwide and the incidence is growing due not only to alcoholism, hepatitis B and C, but also to steatohepatitis. HCC, like renal cell carcinoma and melanoma, is a cancer largely resistant to chemotherapy but the advent of anti-angiogenic, targeted and immune therapies have improved survival for all of these cancers. We hope this review will heighten interest in the field of HCC therapies, provide a clear outline of the current data and strategy for treatment, and sensitize readers to new developments that are likely to emerge in the near future.https://www.mdpi.com/2072-6694/15/9/2506hepatocellular carcinoma (HCC)liverhepatologycancersystemic therapytyrosine kinase inhibitor |
| spellingShingle | Alexander Lazzaro Kevan L. Hartshorn A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy Cancers hepatocellular carcinoma (HCC) liver hepatology cancer systemic therapy tyrosine kinase inhibitor |
| title | A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy |
| title_full | A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy |
| title_fullStr | A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy |
| title_full_unstemmed | A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy |
| title_short | A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy |
| title_sort | comprehensive narrative review on the history current landscape and future directions of hepatocellular carcinoma hcc systemic therapy |
| topic | hepatocellular carcinoma (HCC) liver hepatology cancer systemic therapy tyrosine kinase inhibitor |
| url | https://www.mdpi.com/2072-6694/15/9/2506 |
| work_keys_str_mv | AT alexanderlazzaro acomprehensivenarrativereviewonthehistorycurrentlandscapeandfuturedirectionsofhepatocellularcarcinomahccsystemictherapy AT kevanlhartshorn acomprehensivenarrativereviewonthehistorycurrentlandscapeandfuturedirectionsofhepatocellularcarcinomahccsystemictherapy AT alexanderlazzaro comprehensivenarrativereviewonthehistorycurrentlandscapeandfuturedirectionsofhepatocellularcarcinomahccsystemictherapy AT kevanlhartshorn comprehensivenarrativereviewonthehistorycurrentlandscapeandfuturedirectionsofhepatocellularcarcinomahccsystemictherapy |